Decoding the Next Wave of IO Biomarkers
Senior decision-makers from top pharma, biopharma and therapeutics
Independent of seniority measure above
The ImmunoMark Summit UK Edition returns for its second annual instalment, conceptualized and curated by Convolign Business Consulting. Building on the success of a landmark inaugural edition in 2026, the 2027 summit is larger, more ambitious, and shaped directly by the feedback of the community it serves.
As immunotherapies continue to reshape cancer care, from advanced CAR-T and TCR-T cell therapies to next-generation bispecific antibodies and AI-driven drug discovery, the identification and validation of clinically robust biomarkers has never been more central to oncology success.
Hosted in London, one of the world's foremost centres for life sciences innovation and oncology research, ImmunoMark Summit 2027 brings together pharmaceutical and biotech leaders, translational medicine experts, diagnostic developers, clinical researchers, and regulatory authorities from the UK, Europe, and beyond.
Advanced CAR-T, TCR-T and NK cell therapy innovation for solid tumours, pushing beyond the current standard of care with new modalities and combination strategies.
How artificial intelligence and machine learning are transforming biomarker identification, patient stratification, and translational acceleration at scale.
Advances in spatial biology, single-cell technologies, ctDNA and MRD detection enabling dynamic treatment monitoring and earlier clinical intervention.
Navigating EMA, FDA and MHRA approval strategies, CDx co-development timelines, and health economics frameworks for biomarker-driven solutions.
Special sessions closing the gap between bench science and clinical application, with dedicated focus on translational medicine and evolving regulatory frameworks.
A dedicated Day 1 Drinks and Cocktail Reception providing a relaxed atmosphere to strengthen professional relationships and engage with peers informally.
Latest data, platform innovations, and pipeline insights from world-leading IO and biomarker researchers spanning cell therapies, AI biomarker discovery, and CDx commercialisation.
Network with 400+ senior decision-makers through structured 1:1 sessions, expert panel discussions, networking lunches, and a dedicated Day 1 Drinks and Cocktail Reception.
Leaders from AstraZeneca, Roche, Merck, Johnson and Johnson, Novartis, GSK, and the UK's leading academic institutions presenting at the cutting edge of the field.
Cross-functional panels bridging R&D, clinical, and commercial perspectives, covering reimbursement strategy, investment models, and the business of biomarker-driven oncology.
ImmunoMark Summit UK Edition 2027 is tailored for senior professionals across oncology, biopharma, diagnostics, and the wider life sciences ecosystem.
Seeking the latest therapeutic breakthroughs, novel targets, and clinical trial insights in the evolving IO landscape.
Dedicated to identifying predictive, prognostic, and diagnostic biomarkers and accelerating their path to clinical utility.
Interested in global policies, approval pathways, and the latest guidance on biomarkers and companion diagnostics from EMA, FDA, and MHRA.
Involved in designing, managing, or analysing oncology trials and integrating biomarker strategies into study protocols.
Working on co-development strategies to align diagnostics with targeted therapies, while navigating evolving regulatory requirements.
Supporting biomarker assay development, patient stratification, and regulatory submission processes.
Bridging the gap between bench science and clinical application by leveraging biomarker-driven decision-making and real-time data.
Optimising drug development pipelines through precision medicine approaches and data-driven clinical strategies.
Offering tools, platforms, and services to enhance biomarker discovery, immune profiling, data analytics, and diagnostic innovation.
The United Kingdom is one of the world's most active markets for immuno-oncology and biomarker innovation. The data below illustrates why London is where this conversation belongs.
The UK pharmaceutical oncology market, reflecting the scale of investment and commercial opportunity in cancer treatment and diagnostics.
Annual compound growth rate of the UK biomarker discovery and development market, driven by NHS genomics investment and CDx adoption.
Companion diagnostic tests cleared through MHRA and NICE pathways, one of the most active CDx regulatory environments globally.
Proportion of UK oncology trials now incorporating biomarker-driven patient stratification, reflecting the precision medicine shift across the NHS.
The scale of the UK life sciences sector, underpinning a vibrant ecosystem of pharma, biotech, diagnostics, and research organisations.
UK government investment in the NHS Genomic Medicine Service, creating national infrastructure for biomarker-driven cancer diagnosis and treatment selection.
A high-intensity two-day programme spanning the full spectrum of immuno-oncology and biomarker science, with both streams running simultaneously across dedicated rooms.
| Time | Stream 1: Next-Gen Immuno-Oncology | Stream 2: Biomarkers and Companion Diagnostics |
|---|---|---|
| 08:00 | Registration and Networking Breakfast | |
| 08:45 | Welcome Note by Chairperson | Welcome Note by Chairperson |
| 09:00 | Keynote: The Future of Immuno-Oncology, Beyond Checkpoint Inhibitors | Keynote: Biomarkers as the Foundation of Precision Immunotherapy |
| 09:45 | Engineering Advanced Cell and Gene Therapies for Solid Tumours | Next-Generation Biomarker Platforms: Liquid Biopsy and Multi-Omics |
| 10:30 | Morning Refreshment Break (45 Minutes) | |
| 11:15 | Overcoming Resistance Mechanisms and Tumour Microenvironment Challenges | Biomarker Validation Strategies for Clinical Trial Success |
| 12:00 | AI-Driven Drug Discovery and Translational Acceleration in IO | Companion Diagnostics Development: From Discovery to Regulatory Approval |
| 13:00 | Networking Lunch | |
| 14:00 | Clinical Trial Design in Immunotherapy: Adaptive and Biomarker-Driven Models | Digital Pathology and Spatial Transcriptomics in Oncology |
| 14:45 | Panel: Scaling Immunotherapies from Discovery to Commercialisation | Panel: Regulatory Harmonisation for Biomarker Qualification |
| 15:15 | Evening Refreshment Break (45 Minutes) | |
| 16:00 | Translating Early IO Science into Phase II Success | Machine Learning Applications in Predictive Biomarker Modelling |
| 16:45 | The Next Decade of Immuno-Oncology Innovation | The Future of Biomarker-Driven Oncology |
| 17:30 | Drinks and Cocktail Reception: Day 1 Networking | |
| Time | Stream 1: Next-Gen Immuno-Oncology | Stream 2: Biomarkers and Companion Diagnostics |
|---|---|---|
| 08:00 | Registration and Morning Coffee | |
| 08:45 | Chairperson Opening Remarks | Chairperson Opening Remarks |
| 09:00 | Next-Generation Combination Immunotherapies | Emerging Predictive and Prognostic Biomarkers in IO |
| 09:45 | Manufacturing and Scale-Up Challenges for Advanced Therapies | Real-World Evidence Integration into Biomarker Strategy |
| 10:30 | Morning Refreshment Break (45 Minutes) | |
| 11:15 | Precision Safety Management and Risk Mitigation in IO | Companion Diagnostics Commercialisation and Reimbursement Strategy |
| 12:00 | Translational Research: Bridging Academia and Industry | Multiplex and Programmable Biomarker Platforms |
| 13:00 | Networking Lunch | |
| 14:00 | Panel: Investment and Partnership Models in Immunotherapy | Panel: Global CDx Approval Pathways, EMA, FDA and MHRA Perspectives |
| 14:45 | Summit Closing Remarks and 2028 Outlook | |
ImmunoMark Summit UK Edition 2027 is supported by leading organisations in biopharma, diagnostics, genomics, and life sciences technology. Sponsorship opportunities across all tiers remain available.
Companies who sponsor ImmunoMark Summit to reach a highly concentrated audience of senior immuno-oncology decision-makers, researchers, and diagnostic innovators.
Logos shown are from London 2026. 2027 sponsors are currently being confirmed. Sponsorship opportunities across all tiers remain open.
ImmunoMark Summit is built as a business development platform, not a knowledge conference. Sponsoring the UK Edition 2027 gives your BD team structured access to 400+ senior decision-makers from top pharma, biopharma, biotech, and diagnostics organisations across the UK and Europe. Every element of the programme, from the pre-scheduled 1:1 meetings to the capped exhibition, is designed to produce pipeline conversations, not passive brand awareness.
Your BD team arrives with a pre-built calendar of structured 1:1 meetings with the most relevant decision-makers at the summit. No cold approaches. No time wasted at the booth.
Share your top 20 specific companies and job titles you want introductions to. Our delegate team prioritises bringing them on board so your most important targets are confirmed in the room.
Sponsors have the flexibility to choose preferred speaking slots and curate presentation topics aligned with the summit themes, maximising relevance for your target audience.
Exhibition participation is capped at only 20 exhibitors. This ensures every sponsor has strong visibility, meaningful footfall, and a quality environment free from overcrowding.
Two dedicated streams — Next-Gen Immuno-Oncology and Biomarkers and Companion Diagnostics — ensure your target audience is in the room for every session, not diluted across a general life sciences programme.
Receive access to the full attendee contact list after the event for structured, permission-based follow-up outreach with every delegate who attended ImmunoMark Summit London 2027.
Experience the calibre and energy of an ImmunoMark Summit. Our London 2026 edition brought together over 300 senior life sciences professionals for two days of scientific exchange and strategic networking.
Here is what the scientists, executives, and innovators who attended ImmunoMark Summit London 2026 had to say.
London, UK. Full venue details will be shared with registered delegates and confirmed sponsors. London is home to a world-class concentration of life sciences innovation, oncology research institutions, and pharmaceutical companies, making it the ideal setting for a summit at the intersection of immunotherapy and precision medicine.
The city hosts leading academic medical centres including University College London, Imperial College London, and King's College London, alongside major pharmaceutical operations from AstraZeneca, GSK, Roche, and Johnson and Johnson, all within easy reach of the event venue.
For registration, speaking opportunities, or sponsorship enquiries, our team is ready to assist.
400+ senior leaders. Two streams. One agenda: advancing precision oncology.
Register for Boston Edition